Clinical Trials
55 trialsA Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
Dispatch Biotherapeutics
Viral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBV
Stanford University
PROTA
TILT Biotherapeutics Ltd.
Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma
Huashan Hospital
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
M.D. Anderson Cancer Center
exBOND
CG Oncology, Inc.
Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
TUNIMO
TILT Biotherapeutics Ltd.
LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
Lokon Pharma AB
RACSMEI
Institut Pasteur du Cambodge
VSTs
Children's Hospital Medical Center, Cincinnati
Third Party Viral Specific T-cells (VSTs)
Children's Hospital Medical Center, Cincinnati
A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
Stanford University
TETRAVI
Baylor College of Medicine
TETRAVI Expanded Access Program
Baylor College of Medicine
R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
Columbia University
TRACE
University Hospital Freiburg
Gamma Capture
University of Pittsburgh
ACES
Pediatric Transplantation & Cellular Therapy Consortium
Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer
GeoVax, Inc.
CEDAR
University of Oxford
R-MVST Cells for Treatment of Viral Infections
Columbia University
Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma
Beijing Neurosurgical Institute
BETA-PRIME
EpicentRx, Inc.
Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer
Henry Ford Health System
Prevent
AlloVir
Prevent
AlloVir
First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients.
Orca Therapeutics B.V.
PTN_POPS
Duke University
Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma
Northwestern University
AdUP
University of Birmingham
ACE
Medical College of Wisconsin
CHARMS
AlloVir
BOND
CG Oncology, Inc.
An Exploratory Trial to Evaluate Efficacy and Safety for Combination Treatment of Adenovirus Double Suicide Gene Therapy
Seoul National University Bundang Hospital
Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas
Biogen
Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer
National Institutes of Health Clinical Center (CC)
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
National Institutes of Health Clinical Center (CC)
Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections
Shenzhen Geno-Immune Medical Institute
Theragene
Seoul National University Hospital
NSCLC
Henry Ford Health System
ARMS
AlloVir
Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma
Syneos Health
Effect of AdhAQP1 on Salivary Flow in Patients Treated With Radiation for Head and Neck Cancer
National Institutes of Health Clinical Center (CC)
Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer
Panacela Labs LLC
A Multicenter Randomized Double-blind Placebo-controlled Pilot Study of Safety, Pharmacodynamics and Efficacy of Different Treatments of Immunotherapeutic Drug Mobilan (M-VM3) in Patients With Diagnosed Prostate Cancer
Panacela Labs LLC
Phase I Endovenous Administration of Oncolytic Adenovirus ICOVIR-5 in Patients With Advanced or Metastatic Melanoma
Institut Català d'Oncologia
CHALLAH
Baylor College of Medicine
EAP CHALLAH
Baylor College of Medicine